genentech inc. said_0 third-quarter_profit more_than doubled to $ 11.4 million , or 13 cents_a share , from a depressed 1988 third-quarter performance of $ 5.3 million , or six cents_a share . revenue_rose 23_% to $_100 million from $ 81.6 million . net product sales accounted_for $ 76 million , up from $ 57.5 million a year_earlier . sales of the heart drug tpa were $ 43.6 million , better_than last_year 's depressed third period when the company sold just $ 29.1 million of the drug . but tpa sales fell below levels for this_year 's first and second_quarter sales of $ 48 million , cooling investors . genentech stock fell 12.5_cents in trading_yesterday on the new_york stock_exchange to $ 20.125 . in the nine_months , net_income slid 21_% to $ 28.4 million , or 33_cents a_share , from $ 36 million , or 42 cents_a share . revenues climbed 18_% to $ 289 million from $ 245.3 million . ``_we continue to be on target for ... increasing tpa sales 20_% to 25_% this_year , '' said founder and chief_executive officer robert swanson . but some_analysts remain sour on the company . `` tpa sales are down quarter to quarter . expenses are flat and that 's a good sign . there 's contract revenue from -lcb- limited research and development -rcb- partnerships . but i still think_0 the fundamentals are poor , '' said denise gilbert , an_analyst with montgomery_securities in san_francisco . genentech faces competition in the cardiac-drug market from smithkline beecham plc 's heart drug eminase , expected to receive market approval shortly . and genentech is n't likely_to have any new products ready for market until at_least 1992 , ms. gilbert added 0 . `` the company 's stock is trading at 40 times next_year 's numbers , and that 's too_much , '' she said . on the plus side , genentech is benefiting from a lower tax_rate due to its research outlays , giving a boost to earnings , she said_0 .